Literature DB >> 9673294

A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection.

J Staczek1, H E Gilleland, L B Gilleland, R N Harty, A García-Sastre, O G Engelhardt, P Palese.   

Abstract

The ability of a chimeric influenza virus containing, within the antigenic B site of its hemagglutinin, an 11-amino-acid (AEGRAINRRVE) insert from the peptide 10 epitope of outer membrane (OM) protein F of Pseudomonas aeruginosa to serve as a protective vaccine against P. aeruginosa was tested by using the murine chronic pulmonary infection model. Mice immunized with the chimeric virus developed antibodies that reacted in an enzyme-linked immunosorbent assay with peptide 10, with purified protein F, and with whole cells of various immunotype strains of P. aeruginosa but failed to react with a protein F-deficient strain of P. aeruginosa. The chimeric-virus antisera reacted specifically with protein F alone when immunoblotted against proteins extracted from cell envelopes of each of the seven Fisher-Devlin immunotype strains and had significantly greater in vitro opsonic activity for P. aeruginosa than did antisera from wild-type influenza virus-immunized mice. Subsequent to intratracheal challenge with agar-encased cells of P. aeruginosa, chimeric-virus-immunized mice developed significantly fewer severe lung lesions than did control mice immunized with the wild-type influenza virus. Furthermore, the chimeric influenza virus-immunized group had a significantly smaller percentage of mice with >5 x 10(3) CFU of P. aeruginosa in their lungs upon bacterial quantitation than did the control group. These data indicate that chimeric influenza viruses expressing epitopes of OM protein F warrant continued development as vaccines to prevent pulmonary infections caused by P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673294      PMCID: PMC108472     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Use of monoclonal antibodies to protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages.

Authors:  J L Battershill; D P Speert; R E Hancock
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

2.  Purification and properties of Pseudomonas aeruginosa porin.

Authors:  F Yoshimura; L S Zalman; H Nikaido
Journal:  J Biol Chem       Date:  1983-02-25       Impact factor: 5.157

3.  Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.

Authors:  J M Matthews-Greer; H E Gilleland
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

4.  Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa.

Authors:  H E Gilleland; L B Gilleland; J Staczek; R N Harty; A Garcia-Sastre; O G Engelhardt; P Palese
Journal:  Behring Inst Mitt       Date:  1997-02

5.  Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.

Authors:  H E Gilleland; M G Parker; J M Matthews; R D Berg
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

6.  Evaluation of an immunofluorescent-antibody test for rapid identification of Pseudomonas aeruginosa in blood cultures.

Authors:  G W Counts; R W Schwartz; B K Ulness; D J Hamilton; M J Rosok; M D Cunningham; M R Tam; R P Darveau
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

7.  A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia.

Authors:  J R Starke; M S Edwards; C Langston; C J Baker
Journal:  Pediatr Res       Date:  1987-12       Impact factor: 3.756

8.  Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.

Authors:  H E Gilleland; L B Gilleland; J M Matthews-Greer
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

9.  Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies.

Authors:  L M Mutharia; R E Hancock
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

10.  Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells.

Authors:  J L Schulman; P Palese
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

View more
  16 in total

1.  Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.

Authors:  A A Haller; T Miller; M Mitiku; K Coelingh
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles.

Authors:  Tokiko Watanabe; Shinji Watanabe; Gabriele Neumann; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 3.  RNA virus vectors: where are we and where do we need to go?

Authors:  P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 4.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

5.  Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity.

Authors:  Zhu-Nan Li; Scott N Mueller; Ling Ye; Zhigao Bu; Chinglai Yang; Rafi Ahmed; David A Steinhauer
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.

Authors:  Rika Gomi; Anurag Sharma; Wenzhu Wu; Biin Sung; Stefan Worgall
Journal:  Vaccine       Date:  2017-11-07       Impact factor: 3.641

7.  Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa.

Authors:  B M Price; D R Galloway; N R Baker; L B Gilleland; J Staczek; H E Gilleland
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

Authors:  Stefan Worgall; Anja Krause; Michael Rivara; Kyung-Kim Hee; Enrico V Vintayen; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

9.  A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.

Authors:  Tanweer S Zaidi; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

10.  Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes.

Authors:  Tokiko Watanabe; Shinji Watanabe; Takeshi Noda; Yutaka Fujii; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.